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Background: Cervical cancer and human immunodeficiency virus (HIV) infection/acquired 
immune deficiency syndrome (AIDS) both have a high incidence in South Africa. Cervical 
cancer treatment of HIV-positive women poses challenges. Treatment-related changes in 
quality of life (QOL) of such women are important to future treatment protocols.
Aim: To examine demographic data of HIV-negative and HIV-positive women at diagnosis of 
cervical cancer and describe their changes in QOL as a result of treatment.
Methods and materials: All newly diagnosed patients with cervical cancer at Tygerberg 
Hospital were approached to participate in the study. The European Organisation for 
Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) 
and the Cervix Cancer Module (QLQ-CX24) were used. General QOL was measured with 
the EORTC QLQ-C30 and cervical-specific QOL with the QLQ-CX24 questionnaire. The 
patients completed the questionnaire at diagnosis, on completion of treatment and at 
3 months’ follow-up.
Results: The study included a total of 221 women of whom 22% were HIV-positive; the 
latter were younger and of higher educational level than the rest. Mean monthly income and 
stage distribution was similar between the two groups. HIV-positive patients underwent 
radiation therapy more commonly than chemoradiation. HIV-positive women showed 
statistically significantly higher loss to follow-up during the study. HIV-positive women 
experienced no improvement in insomnia, appetite loss, nausea, vomiting, diarrhoea, social 
role or any of the sexual domains. In contrast, HIV-negative women experienced statistically 
significant improvement in all sexual domains other than sexual/vaginal functioning. The 
QOL improvement of HIV-negative women was statistically significantly greater than their 
HIV-positive counterparts in the majority of QOL domains. Global health improved in both 
groups, with HIV-negative women experiencing greater improvement. HIV-positive women 
experienced an initial decline of peripheral neuropathy (PN) symptoms post treatment with 
a return to pretreatment values at 3 months’ follow-up. The change in PN was statistically 
significant between the HIV-negative and HIV-positive women.
Conclusion: Demographic differences exist between the HIV-negative and HIV-positive 
groups. The differential outcome in the QOL of HIV-positive and HIV-negative women treated 
for cervical cancer might be related to persistence of AIDS-related symptoms on completion of 
cervical cancer treatment.
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Introduction
The quality of life (QOL) of human immunodeficiency virus (HIV)-positive women with cervical 
cancer is the result of both diseases and the impact of their respective treatments. Invasive cervical 
cancer is an acquired immune deficiency syndrome (AIDS)-defining condition (World Health 
Organization stage 4).1 AIDS is endemic in sub-Saharan Africa. The South African population 
has a 12% – 18% incidence of HIV-positivity.2 South Africa has a cervical cancer incidence rate of 
26.8/100 000.3 Most South African women present at an advanced stage of the disease. Cervical 
cancer and HIV infection are epidemiologically related owing to the sexual transmission of 
both conditions. Peripheral neuropathy (PN) in HIV-infected persons occurs in 50% – 60% of 
cases. At autopsy, PN can be shown in all HIV-positive persons despite their having no signs or 
symptoms during their lifetime. Antiretroviral medication (particularly didanosine, zalcitabine 
and stavudine) is directly neurotoxic and results in PN identical to AIDS-associated neuropathy. 
The disease and its treatment synergistically increase PN. Cisplatin is the drug of choice in 
chemoradiation (CR) treatment of cervical cancer. Cisplatin results, in a dose-dependent fashion, 
in sensory PN in the stocking-glove distribution.4 Poor tolerance of chemotherapy for cervical 
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cancer by HIV-positive women results in substantially less 
completion of CR than their HIV-negative counterparts. 
The use of CR in advanced stage (III to IVA) cervical cancer 
in HIV-positive women has been questioned owing to 
the limited survival benefit.5 A Cochrane review shows a 
statistically non-significant 3% benefit in 5-year survival of 
CR over radiation therapy (RT) in stage III to IVA.6 Simonds 
et al.5 suggest that the omission of chemotherapy in these 
HIV-positive women with cervical cancer would result in 
timely completion of the full dose of radiation therapy.
A limitation of the study by Simonds et al.5 was the 15.4% 
(59 out of a cohort of 383) incidence of HIV-positive women.5 
Data on the impact of RT on QOL of HIV-positive women 
with cervical cancer are lacking. The aim of the present study 
was to examine demographic data for HIV-negative and 
HIV-positive women at diagnosis of cervical cancer and to 
describe QOL changes in these women after treatment for 
cervical cancer.
Methods and materials
Inclusion criteria
Patients referred to the Unit of Gynaecologic Oncology at 
Tygerberg Hospital who had newly diagnosed cervical 
cancer were approached to participate in the study. The unit 
is one of two tertiary referral units for public-sector patients 
in Western Cape Province. The province has a population of 
5.8 million. Most (85%) of the population do not have private 
medical insurance and are dependent on public facilities 
provided by two tertiary hospitals (Tygerberg Hospital and 
Groote Schuur Hospital) for treatment of cervical cancer.7 
Patients were eligible for the study if they had histologically 
proven cervical cancer. Exclusion criteria included concurrent, 
or previous history of, cancers and medical disorders that 
might affect QOL, such as diabetes. Patients unable to 
provide informed consent owing to psychiatric disorders 
were excluded. Cervical cancer was staged according to 
international guidelines .8 Clinical management included 
HIV testing and initiation of antiretroviral treatment. HIV-
positive women did not receive chemotherapy if their CD4 
count was < 200 cells/µL, or active tuberculosis was present.
Questionnaires
Patients completed the questionnaire in the language of 
their choice (isiXhosa, English or Afrikaans) after informed 
consent was obtained.9 A research assistant helped 
illiterate patients. To exclude bias, the research assistant 
had no medical background and was not involved in 
clinical management of the patients. Questionnaires were 
completed prior to treatment, after initial treatment, and 
after a 3-month post-treatment period. The follow-up visits 
coincided with clinical follow-up of patients. Patients failing 
to attend visits were contacted telephonically where possible. 
Patient records were used to extract relevant clinical data. 
Ethical approval was obtained from the local committee 
(S12/06/174). Clinical management followed protocols 
as previously described.5 The European Organisation for 
Research and Treatment of Cancer (EORTC) Quality of 
Life Core Questionnaire (EORTC QLQ-C30) and the Cervix 
Cancer Module (QLQ-CX24) were both used. The EORTC 
QLQ-C30 consists of 30 items comprising 5 functional scales 
(physical, role, emotional, social and cognitive), 3 symptom 
scales (fatigue, nausea/vomiting and pain), an overall QOL 
scale, and 6 individual items (dyspnoea, insomnia, appetite 
loss, constipation, diarrhoea, and financial difficulties). The 
EORTC QLQ-C30 was analysed according to the procedures 
recommended by the EORTC QOL Group. Higher scores on 
the QLQ-C30 functioning scales and the overall QOL scale 
indicate a better QOL. Higher scores on the symptom and 
individual item scales represent a decrease in QOL.10 The 
EORTC QLQ-CX24 includes 3 multi-item scales (symptom 
experience, body image, and sexual functioning) and 5 single-
item scales (lymphoedema, lower back pain, menopausal 
symptoms, tingling and numbness, and sexual enjoyment). 
Higher scores indicate a decrease in QOL except for items 
49 and 54 (where higher scores indicate better QOL).11 The 
questionnaires used were translated and validated for use in 
South Africa.9
Statistical analysis
Descriptive statistics were used to characterise the 
study sample in terms of the contextual factors of socio-
demographic and medical variables. Data presented as 
medians were analysed using Kruskal–Wallis tests. Post hoc 
analyses were done with Fisher’s least significant difference 
(LSD) test. Chi-square tests were used for categorical data. 
A p value < 0.05 was considered to be significant. Statistical 
analysis was performed with the use of STATISTICA version 
12 software.
Results
Demographic characteristics
The study included a total of 221 women (Table 1). HIV-
positivity of the study group was 22%. The mean age of 
the HIV-positive women was statistically significantly 
7 years less than that of the HIV-negative women. Age had 
a normal distribution without any outliers. HIV-positive 
women had a higher educational grade. Racial distribution 
shows a statistically significant difference between black 
(40%), mixed race (12%) and white (0%) participants’ 
HIV-positivity rates. Mean monthly income as well as the 
percentage of patients under the poverty line were not 
statistically significantly different between the HIV-positive 
and -negative groups. Single women had a statistically 
significantly higher rate of HIV-positivity than their married, 
widowed and divorced counterparts. The stage distribution 
of HIV-negative and HIV-positive cases was not statistically 
significantly different. HIV-positive patients underwent RT 
more commonly than CR.
Unemployed women had a statistically significantly higher 
HIV-positivity rate (26%) than the employed women (23%). 
The loss to follow-up of HIV-positive women v. HIV-negative 
women during the post-treatment (56% v. 34%) and 3-month 
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(38% v. 30%) follow-up visits was statistically significantly 
higher for the HIV-positive women (Figure 1). Cause and 
confirmation of death could be accurately determined in 
20 women in the total study population.
HIV status and change in quality of life over the 
study period
The domains of dyspnoea, financial difficulties, 
lymphoedema and menopausal symptoms remained 
unchanged during the study period. HIV-positive women 
experienced no improvement in insomnia, appetite loss, 
nausea and vomiting, diarrhoea, social role or any of the 
sexual domains over the study period. In contrast, HIV-
negative women experienced statistically significant 
improvement in all sexual domains other than sexual/
vaginal function. The improvement in QOL of HIV-negative 
women was statistically significantly more than their HIV-
positive counterparts in all domains, with the exception of 
role function, insomnia, constipation, sexual worry and 
sexual activity (Table 2). Global health improved in 
both groups, with HIV-negative women experiencing a 
greater improvement. PN did not change in HIV-negative 
women but HIV-positive women experienced an initial 
decline in this symptom at post treatment with a return 
to pretreatment values at the 3-month follow-up visit. 
The change in PN was statistically significantly different 
between HIV-negative and HIV-positive women.
Discussion
The results of the study show significant demographic 
differences between HIV-positive and HIV-negative 
women with a diagnosis of cervical cancer. The former 
group is statistically younger, and has a higher educational 
level and higher unemployment rate than the latter. Black 
women have a statistically higher HIV-positivity rate than 
mixed race and white women. Single women had the 
highest HIV-positivity rate. Monthly income is similar in 
both groups. RT was more frequently used than CR in HIV-
positive patients. The 22% HIV-positive rate in the current 
study is higher than previously reported rates. This change 
is the result of a general change in HIV-positive rates in the 
total population over time.2 Black women had a higher HIV-
positive rate than mixed race or white women. A previous 
study documented a higher incidence (30%) of positive 
syphilis serology amongst black women with cervical 
cancer than in their white and mixed race counterparts.12 
The younger age of HIV-positive cervical cancer patients 
confirms previous studies of HIV in cervical cancer cases. 
In previous studies, the difference in mean age between 
TABLE 1: Comparative demographic data of HIV-negative and HIV-positive 
women (poverty line as defined by the Western Cape Provincial Government).
Characteristics HIV-negative  
n = 173
HIV-positive 
n = 48
p value
Age (years) 51.34 43.94 p < 0.01
 Mean education level (grade) 7 8 p < 0.05
Race (%) - - p < 0.05
 Mixed race people 88 12 -
 Black people 60 40 -
 White people 100 0 -
Income (ZAR) 1450 1576 NS
 Below poverty line of R3500 (%) 79 21 NS
Marital state (%) - - p < 0.05
 Single 68 32 -
 Married 88 12 -
 Widow 86 14 -
 Divorced 94 6 -
Stage distribution - - NS
Treatment (%) - - p < 0.05
 Radiotherapy 75 25 -
 Chemoradiation therapy 88 12 -
Employment (%) - - p < 0.05
 Employed 77 23 -
 Pensioner 93 7 -
 Unemployed 74 26 -
Source: Western Cape Provincial Treasury. Regional development profile City of Cape 
Town. 2012 [cited 2014 Jul 23]. Available from: http://www.westerncape.gov.za/assets/
departments/treasury/dc0_city_of_cape_town_sep-lg_profile_02_2013.pdf
NS, not significant.
TABLE 2: Change in quality of life during study period.
Quality of life domain HIV- n = 173 HIV+ n = 48 HIV- versus HIV+
Physical function p < 0.01† p  < 0.05† p < 0.05
Role function p < 0.01‡ p < 0.01‡ NS
Dyspnoea NS NS NS
Pain p < 0.01‡ p < 0.01‡ p < 0.01
Fatigue p < 0.01‡ p < 0.01‡ p < 0.01
Insomnia p < 0.01‡ NS NS
Appetite loss p < 0.01† NS p < 0.01
Nausea and vomiting p < 0.01‡ NS p < 0.01§
Constipation p < 0.01† p < 0.05† NS
Diarrhoea NS NS p < 0.01
Cognitive function p < 0.01‡ p < 0.05‡ p < 0.01
Emotional role p < 0.01‡ p < 0.01‡ p < 0.05
Social role p < 0.01† NS p < 0.05
Financial difficulties NS NS NS
Global health status p < 0.01† p < 0.01† p < 0.01
Symptom experience p < 0.01‡ p < 0.05‡ p < 0.01
Lymphoedema NS NS NS
Peripheral neuropathy NS p < 0.01‡ p < 0.01
Menopausal symptoms NS NS NS
Body image p < 0.01† p < 0.01† p < 0.05
Sexual worry p < 0.01‡ NS NS
Sexual activity p < 0.01† NS NS
Sexual/vaginal functioning NS NS p < 0.01
Sexual enjoyment p < 0.05† NS p < 0.01
NS, not significant.
†, Improved; ‡, decreased; §, HIV+ >HIV-. 
All other p values in column HIV- >HIV+.
FIGURE 1: Follow-up of HIV-negative versus HIV-positive women over the study 
period.
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HIV-negative and HIV-positive patients was reported 
as 10 years, whilst the current study shows a 7-year age 
difference.5,13,14 The stage distribution in the current study 
was similar in HIV-negative and HIV-positive women. 
Despite the similar stage distribution, significantly more 
HIV-negative than HIV-positive women received CR. The 
selection by the presiding clinician of the inability of HIV-
positive women to tolerate the chemotherapy because of 
low CD4 counts, gave rise to this difference.
The majority of QOL domains in HIV-negative women 
improved with treatment with prolonged effect up to 
3 months’ follow-up. Improvement of QOL domains in HIV-
positive women was statistically less than in HIV-negative 
women. PN domain did not change in HIV-negative women. 
In HIV-positive women, initial improvement occurred in PN 
with relapse to pretreatment level at 3 months. Appetite loss 
in HIV-positive women initially improved after treatment 
and returned to pretreatment levels at 3 months’ follow-up. 
HIV-negative women showed an improvement in appetite 
loss up to 3 months’ follow-up. The QOL of HIV-negative 
women significantly improved in the majority of domains. 
HIV-positive women had fewer domains improved by 
treatment, and the magnitude of improvement was less 
than that amongst HIV-negative women. Temporary 
improvement of pain, fatigue and appetite loss after 
treatment in HIV-positive women reverted to pretreatment 
levels at 3 months’ follow-up. Pain and fatigue are AIDS-
related conditions that are prevalent in AIDS patients, 
despite adequate treatment. Depression is associated with 
these symptoms, and the difference in emotional functioning 
in the current study underlines the element of depression 
in the HIV-positive women.15 The AIDS-related impact on 
QOL accounts for these relapses in QOL domains. Diarrhoea 
was significantly more in HIV-positive women than in HIV-
negative women, and treatment did not change the incidence 
in either group. Diarrhoea is commonly associated with 
AIDS and can have numerous causes, both infectious and 
non-infectious, for example AIDS medication-related gastro-
intestinal side-effects.16 Constipation improved in both HIV-
negative and HIV-positive women. Radiation is associated 
with increased stool frequency owing to radiation-induced 
mucosal rectal damage. PN paradoxically improved in both 
groups after treatment and reverted to pretreatment levels 
in HIV-positive women. Contrary to expected cisplatin-
related toxicity, treatment did not result in an increase of PN. 
The dose of cisplatin, which did not reach the cumulative 
threshold dose > 250 mg – 350 mg/m², may explain the 
absence of PN. Cisplatin-associated PN may occur up to 
8 months after exposure, and therefore longer follow-up may 
reveal PN.17
In the present study, higher rates of loss to follow-up 
occurred in HIV-positive women. A meta-analysis of sub-
Saharan low- and middle-income countries’ antiretroviral 
treatment programmes reports on causes of loss to 
follow-up. Self-transferring care to other facilities (18.6%), 
unreported death (38.8%) and stopping treatment were 
identified as the major reasons for loss to follow-up.18 
WHO AIDS stage 3 and 4 cases have a mortality rate 
of 72.12 per 100 person-years in the first 6 months after 
initiation of treatment. The mortality rate decreases to 7.9 
per 100 person-years after 12 months.19 The mortality rate 
is compounded by cervical cancer-related death. In a South 
African study, the mortality rate after treatment of stage III 
cervical cancer was the highest in the first 6 months after 
treatment.12 In Kenya, a 41% loss to follow-up occurred in 
women receiving treatment for cervical cancer.20 Tracking 
of women after missed appointments is not done routinely 
owing to resource constraints.18 Verifying HIV-related 
deaths by checking death certificates is subject to 90% 
misclassification of HIV deaths in South Africa.21
Limitations of the present study include a short follow-up 
subsequent to completion of therapy. The short follow-
up limits the conclusion to long-term effects of treatment. 
Prolonged follow-up may reveal an increased incidence of 
PN. The higher loss to follow-up rate of HIV-positive women 
during the study period precludes sub-analysis of smaller 
groups, for example treatment-related PN in those women 
undergoing CR.
In conclusion, the study documents the demographic 
difference in HIV-negative and HIV-positive women with 
cervical cancer with regard to a younger age in the latter 
group. The 5-year survival benefit of CR in comparison 
with RT in HIV-negative women with stage III to IVA is a 
statistically non-significant 3%.6 The poor response of HIV-
positive women to CR raises the question of whether CR is 
appropriate in these circumstances.5 A significant difference 
exists in the short term in certain QOL domains of HIV-
positive women with cervical cancer receiving RT or CR. In 
these circumstances, the different impact on long-term QOL 
of HIV-positive women with cervical cancer receiving RT or 
CR warrants further study.
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